Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/1/2021 | $78.00 | Buy | HC Wainwright & Co. |
10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)
DEFA14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)
DEF 14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events. The Company's 2024 events to date are listed below: Feb 29 - Mar 1, 2024 – GBG Annual Scientific Meeting (German clinical network conference)Jun 1 - 4, 2024 – American Society of Clinical Oncology (ASCO) Annual MeetingJun 3 - 6, 2024 – BIO International Convention (partnering conference)Jun 4 - 6, 2024 – Jefferies Global Healthcare Confer
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01. To date, approximately 30 out of 38 sites have conducted site initiation visits (SIVs). An SIV is followed by site activation, HLA
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024. CEO Snehal Patel commented, "The addition of our company to the Russell 2000 Index may further increase our institutional ownership as it did in
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. United Security Bancshares The Trade: United Security Bancshares (NASDAQ:UBFO) Director Jagroop Gill acquired a total of 14
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024. CEO Snehal Patel commented, "The addition of our company to the Russell 2000 Index may further increase our institutional ownership as it did in 2021 and is a reflection of the progress we have m
The company announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement. The closing of the private placement is expected to occur on or about June 18, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately $2.5 million, before deducting offering expenses payable by the Company. Greenwich intends to use the net proceeds from the offering for clinical development and working capital. No investment banking fees are b
HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)